Literature DB >> 22682723

Comparison of cervical mucus of 24/4 vs. 21/7 combined oral contraceptives.

Rachel Steward1, Alexander Melamed, Anna Granat, Daniel R Mishell.   

Abstract

BACKGROUND: Few studies have examined the action of combined oral contraceptives (COCs) on cervical mucus. We hypothesized that midcycle cervical mucus of women taking COCs is of poor quality when compared to their own midcycle mucus prior to initiating COCs. We sought to compare the effect upon quality and sperm penetration of the cervical mucus on the last hormone-free day with a 24/4 regimen to a 21/7 regimen.
METHODS: This is an open-label, investigator-blinded, randomized, controlled, crossover equivalency study. All subjects received, in random order, 2 months of a 21/7 regimen and 2 months of a 24/4 regimen, each containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate. Analysis of cervical mucus quality (CMQ) and sperm penetration took place midcycle and on the last day of the hormone-free interval during the second month of each COC treatment.
RESULTS: From April 2010 to November 2011, 18 subjects completed all study visits. Mean midcycle CMQ was poor (mean CMQ=1) and did not differ between 24/4 and 21/7 regimens (p=.92). On the last day of the pill-free interval, the quality and sperm penetration were poor with both regimens.
CONCLUSION: This study indicates that thickening of cervical mucus is a major mechanism of contraceptive action of COCs and that both 21/7 and 24/4 regimens result in poor quality and impenetrable mucus on the last day of the pill-free interval.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22682723     DOI: 10.1016/j.contraception.2012.05.004

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  3 in total

1.  Response to: Pharmacokinetic and Pharmacodynamic Drug Interactions between Antiretrovirals and Oral Contraceptives.

Authors:  Jessica Maria Atrio
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

2.  The effect of protease inhibitors on the cervical mucus of HIV-positive women taking norethindrone contraception.

Authors:  Jessica Atrio; Alice Stek; Hita Vora; Lorraine Sanchez-Keeland; Ferdous Zannat; Melissa Natavio
Journal:  Eur J Contracept Reprod Health Care       Date:  2014-10-06       Impact factor: 1.848

Review 3.  Fragile X Associated Primary Ovarian Insufficiency (FXPOI): Case Report and Literature Review.

Authors:  Dorothy A Fink; Lawrence M Nelson; Reed Pyeritz; Josh Johnson; Stephanie L Sherman; Yoram Cohen; Shai E Elizur
Journal:  Front Genet       Date:  2018-11-27       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.